s also mainly include employee benefits expenses. The significant revenue streams are detailed below, consistently with the business review presented in the management report 
*Financial intercompany position between segments is excluded from the assets and liabilities of the segment. For the year-ended December 31, 2023, the 
Group revenue was EUR 428.7 million, a 18.7% 
increase from 2022 (2022: EUR 361.3 million), primarily composed of: External revenues for the Proton Therapy 
and Other Acce